Creo set to disrupt with proprietary process

Creo, an ingredient company with a platform for producing rare cannabinoids, such as CBG, announces its official launch.

Read More

Creo produces CBG/A at demo scale

FORMULE VERTE

The U.S. company specializing in cannabinoids announced production of CBG and CBGA at demo scale.

Read More

Cannabinoids drug maker GW to be acquired

THE WALL STREET JOURNAL

Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from the marijuana plant, for $6.7 billion in cash and stock.

Read More

Nothing found.

This company wants to bring the ‘mother cannabinoid’ to the masses

Creo News

THE HILL

Using biosynthesis, rarer cannabinoids could be better accessible and help many more people with their health and wellness needs.

Creo first to achieve demo production of CBGA

Creo News

CBD HEALTH&WELNESS

Creo has produced CBG and CBGA through fermentation at 12,500-liter scale, with performance matching or exceeding expectations.

Flavor and fragrance is embracing biotech

Industry Article

CHEMICAL ENGINEERING NEWS

ASF said biotechnology is its answer to meeting rising demand for natural ingredients while avoiding the pitfalls of sourcing plant-based substances.

Rare cannabinoids are coming

Industry Article

NEW FRONTIER DATA

Poll found CBG is best known of the minor cannabinoids. A significant number of respondents viewed minor cannabinoids as having the most growth potential.

Nothing found.

US company first to produce CBGA at scale

CANNABIZ

Creo, a US ingredient company, has produced cannabigerol (CBG) and cannabigerolic acid (CBGA) through fermentation at 12,500-litre scale.

Read More

Creo first to achieve demo production of CBGA

BIOFUELS DIGEST

Creo has become the first company to produce cannabigerol (CBG) and cannabigerolic acid (CBGA) through fermentation at 12,500-liter scale.

Read More

Synthetic biology: The next step in the cannabinoid revolution

LABIOTECH

While most endeavors focus on extracting cannabinoid compounds from cannabis plants, there’s a growing interest in producing them using engineered microbes.

Read More

The cannabinoid revolution

CBD HEALTH AND WELLNESS

The world is on the cusp of a breakthrough that could change how we approach our health, beauty, and wellbeing.

Read More

Company has partnered with Genomatica, raised $50m

SAN DIEGO BUSINESS JOURNAL

San Diego-based startup Creo, an ingredient company that produces rare and novel cannabinoids, has officially launched after spending four years in research and development mode...

Read More

Genomatica collaborates to create Creo, a cannabinoid company

GLOBAL COSMETIC INDUSTRY MAGAZINE

Creo, a cannabinoid ingredient company, in collaboration with Genomatica, has been officially launched to develop fermentation-based cannabinoid technologies.

Read More

Nothing found.

Frequently asked questions

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Creo has a platform for producing cannabinoids as ingredients developed exclusively with its joint venture partner, biotech industry leader Genomatica. Creo’s partner has successfully commercialized fermentation-based processes for plastics, cosmetics and apparel. Creo has the technology to deliver a reliable, high-quality and consistent supply of cannabinoid ingredients at commercial scale.

Creo was formed and continues to be based in the US, with headquarters in Southern California.

Creo’s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet.

Creo’s brand is built on three core pillars: sustainable innovation, access to abundance and being a trusted partner to customers. Creo makes its cannabinoid ingredients using one of the world’s oldest natural processes - fermentation. Fermentation requires less water, energy and land than the plant-based approaches typically used to extract cannabinoid ingredients. This gives Creo the ability to support the development of innovative new products without causing unnecessary harm to the planet. Creo’s ingredients are of the very highest quality, containing none of the contaminants often associated with plant-derived ingredients.

Cannabinoids are molecules that interact with the body’s endocannabinoid system (ECS). Phytocannabinoids are those cannabinoids that occur naturally in plants, most commonly the cannabis plant. THC and CBD are the most common phytocannabinoids but there are over 100 additional phytocannabinoids that have been identified. The body also produces its own cannabinoids known as endocannabinoids.

The endocannabinoid system (ECS) within the human body is made up of cannabinoid receptors and endocannabinoids. The receptors are located throughout the body including in the brain, nervous system, skin, immune cells, bone, fat tissue, blood vessels and various organs. The ECS is involved in the regulation of pain, stress, inflammation, appetite, energy, cardiovascular function, reward, sleep and other processes.

CBG, sometimes called the “mother cannabinoid” or “skin cannabinoid,” is the parent molecule from which other cannabinoids are made in the cannabis plant. But since it’s mostly converted into other cannabinoids, such as THC and CBD, very little of it remains intact in the plant (typically <0.5% by weight). Due to its scarcity, up until now, customers and patients have struggled to access the benefits of this important non-intoxicating cannabinoid. Plant cannabinoids are naturally produced in the acid form. Prior to consumption, they are typically converted into their non-acid form (“decarboxylated”) by heating. In this way, CBG is made from CBGA.

Scientific researchThere is a growing body of exciting scientific research into CBG, both on its own as well as in combination with other cannabinoids. Areas of research include:

  • Antibacterial (e.g. MRSA, dental plaque)
  • Dry skin
  • Skin inflammation
  • GI inflammation
  • Neuroinflammation and neurodegeneration
  • Insulin resistance
  • Ocular tension
  • Loss of appetite
  • Mood disorders
  • Neuropathic pain

Plant extraction presents a number of challenges and uses large amounts of land, water and often electricity. Additionally:

  • Plant extracts have variable consistency
  • Cultivated plants are prone to contamination and impurities
  • Presence of THC creates regulatory complications
  • Plant extraction is impractical and expensive for rarer cannabinoids
  • Only seasonal availability

The process Creo has developed provides pure, consistent, single molecules that it can produce at scale, contaminant free, with a smaller environmental footprint all year round.

No. Through Creo’s fermentation process it produces natural CBG without the use of the cannabis plant.

Yes, there are more than 100 cannabinoids known in the plant but only two are currently being actively exploited (THC & CBD). Creo specializes in producing a wide variety of rare and novel cannabinoids, beginning with CBG (Cannabigerol).

Creo’s technology and process are patented and proprietary with freedom-to-operate, so customers can rely on Creo to be a trusted supplier.

Creo’s products are manufactured and packaged in an FDA registered food grade facility in the US.

Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.

DOWNLOAD NOW

Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.

DOWNLOAD NOW

Press kit

Creo, a cannabinoid ingredient company, set to disrupt industry amid launch with proprietary process & technology.

DOWNLOAD NOW